RxDoctor Payments Data

Alexis Dieter, MD

Urogynecology and Reconstructive Pelvic Surgery · Washington, DCNPI 1346408994

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,628 of the $3,130 with a category attached, or 83.9%. 10 manufacturers reported payments, led by Coloplast at 57.4% of the total. Reporting peaked in 2022 at $1,329 and has fallen 61.2% since, to $515 in 2025.

$3,130in general payments, 2019–2025

Across 32 payments — averaging $97.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Boston Scientific$540
  • Axonics, Inc.$411
  • Conmed Corporation$169
  • Caldera Medical, Inc$74
  • Intuitive Surgical$44
  • plus $96 from 4 others
$181,408in research payments, 2019–2025

Across 31 payments — averaging $5851.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$181K

What the payments were for

  • Travel & lodging$50216%
  • Food & beverage$2,62884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$85,759
Medicare patients
192
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron42$32,078
MyrbetriqMirabegron31$28,199
Trospium Chloride ErTrospium Chloride50$11,400
Estradiol50$3,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$22$32,07842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →